Key Drivers
- High gross margin
- Negative free cashflow
- Elevated long-term leverage
AIAI Summary
Tandem's shift to a pharmacy/Pay‑Go recurring‑revenue model (plus a software/closed‑loop roadmap) meaningfully improves upside via higher gross margins and predictable lifetime value, but the investment now critically depends on rapid payer/pharmacy adoption and sustained margin expansion to service elevated convertible debt—so monitor pharmacy coverage wins, recurring‑revenue mix, and consecutive quarters of positive adjusted EBITDA as the decisive catalysts/risks.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High gross margin
- •Negative free cashflow
- •Elevated long-term leverage
TNDM combines strong gross margins and recent quarterly operating improvement with full-year losses, negative FCF, and high long-term leverage that raise solvency and accumulation-of-losses concerns.
Price Behavior
Key Price Behavior Insights:
- •Short-term uptrend
- •Range-bound medium-term
- •Volatile spikes
Over the last month the stock has been roughly flat-to-mildly up with a short-term recovery from $21.59 supporting a bullish momentum bias but upside is capped by resistance near $26.00–$28.26 amid elevated volatility.
Sharp spike to $28.26 on 2026-02-23 followed by a pullback into
Sentiment & News
Key News Insights:
- •Margin expansion
- •Pay-as-you-go
- •Convertible notes
Tandem reported strong Q4 margins and product progress while shifting to pay-as-you-go and pharmacy reimbursement, raised convertible debt, and saw volatile stock moves amid institutional buying and a consensus Hold.
Financing and product momentum bolster longer-term upside but near-term revenue smoothing and dilution risk will likely keep the stock volatile
Similar Companies in Healthcare
Other companies in the same sector with AI ratings